Palisade Bio (PALI) Net Cash Flow Growth (1y) (2011 - 2026)
Palisade Bio (PALI) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 53.46% |
| 10 | Palisade Bio | 422.47 Mn | 289.84 Mn | - | 70.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.78% |
| Dec 31, 2025 | 7,097.47% |
| Sep 30, 2025 | 94.27% |
| Jun 30, 2025 | -2,454.55% |
| Mar 31, 2025 | -124.13% |
| Dec 31, 2024 | 161.84% |
| Sep 30, 2024 | -203.67% |
| Jun 30, 2024 | -97.52% |
| Mar 31, 2024 | -226.48% |
| Dec 31, 2023 | -79.78% |
| Sep 30, 2023 | -112.12% |
| Jun 30, 2023 | 286.90% |
| Mar 31, 2023 | 123.73% |
| Dec 31, 2022 | 55.61% |
| Sep 30, 2022 | 520.61% |
| Jun 30, 2022 | -114.17% |
| Mar 31, 2022 | -3,829.59% |
| Dec 31, 2021 | -9,397.37% |
| Sep 30, 2021 | 288.93% |
| Jun 30, 2021 | 268.06% |